CD8A and cancer: The most studied receptor of CXCL10 is CXCR3 (LR pair associated with immune response in 12 of the 18 cancer types, Figure 4A), which is expressed by effector CD8+ T cells, T helper 1 cells, and NK cells, which are all antitumor lymphocytes.12